Početna › Limfom › Pennsylvania
Kliničke studije za Limfom u državi Pennsylvania
24 studija za Limfom traži sudionike na lokacijama u državi Pennsylvania.
Gradovi u državi Pennsylvania
Službeni tekst studije (engleski)
Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
U tijeku regrutacijaOpažajna studija
Od 0 do 38 godina · Oba spola · Ažurirano 1. lis 2026. · NCT06131801A First-in-Human Study of KK2223 in Participants With Relapsed or Refractory T Cell Non-Hodgkin Lymphoma
- University of Pennsylvania - Abramson Cancer Center, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07192471A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
- University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 30. ruj 2026. · NCT07015242A Study of Repotrectinib in Pediatric and Young Adult Subjects Harboring ALK, ROS1, OR NTRK1-3 Alterations
- Children's Hospital of Philadelphia-Center for Childhood Cancer Research, Philadelphia
U tijeku regrutacijaFaza 1/2
Do 25 godina · Oba spola · Ažurirano 25. ruj 2026. · NCT04094610Phase I Trial to Determine the Dose and Evaluate the PK and Safety of Lutetium Lu 177 Edotreotide Therapy in Pediatric Participants With SSTR-positive Tumors
- The Children's Hospital of Philadelphia (CHOP), Philadelphia
U tijeku regrutacijaFaza 1
24 Months – 18 Years · Oba spola · Ažurirano 25. ruj 2026. · NCT06441331A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
- UPMC Hillman Cancer Center, Pittsburgh
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 17. ruj 2026. · NCT07221500Collection of Tissue Samples for Cancer Research
- University of Pittsburgh Medical Center, Pittsburgh
U tijeku regrutacijaOpažajna studija
2 Months · Oba spola · Ažurirano 16. ruj 2026. · NCT00900198AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.
- Research Site, Philadelphia
U tijeku regrutacijaFaza 1/2
Od 12 godina i više · Oba spola · Ažurirano 14. ruj 2026. · NCT06137144CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
U tijeku regrutacijaFaza 1/2
12 Months – 21 Years · Oba spola · Ažurirano 11. ruj 2026. · NCT04870944Surovatamig as Consolidation Therapy in Participants With Chronic Lymphocytic Leukaemia or Small Lymphocytic Lymphoma With Unmutated Immunoglobulin Heavy Chain Variable (IGHV)
- Research Site, Pittsburgh
U tijeku regrutacijaFaza 3
Od 18 do 18 godina · Oba spola · Ažurirano 8. ruj 2026. · NCT07509151A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
- Thomas Jefferson University, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 8. ruj 2026. · NCT06624085TLN-121 in Relapsed or Refractory Non-Hodgkin Lymphomas
- Hospital of the University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 4. ruj 2026. · NCT07082803Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
- Lehigh Valley Topper Cancer Center Institute, Allentown
- Thomas Jefferson University, Philadelphia
- West Penn Hospital, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 25. kol 2026. · NCT05826535A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas
- Abramson Cancer Center of the University of Pennsylvania, Philadelphia
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 19. kol 2026. · NCT04104776A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
- Allegheny Health Network, Pittsburgh
U tijeku regrutacijaFaza 3
Od 18 godina i više · Oba spola · Ažurirano 4. kol 2026. · NCT07188558DALY II USA/ MB-CART2019.1 for DLBCL
- Allegheny Health Network Cancer Institute, Pittsburgh
U tijeku regrutacijaFaza 2
Od 18 godina i više · Oba spola · Ažurirano 13. srp 2026. · NCT04792489Anti-CD7 CAR-T Cells in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia or Lymphoma
- Children's Hospital of Philadelphia, Philadelphia
U tijeku regrutacijaFaza 1
Od 0 do 29 godina · Oba spola · Ažurirano 7. srp 2026. · NCT06934382A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
- University of Pennsylvania, Abramson Cancer Center, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 2. srp 2026. · NCT05131022A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas
- Dren Investigational Site 2, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 17. lip 2026. · NCT05475925Effects of Dexrazoxane Hydrochloride on Biomarkers Associated With Cardiomyopathy and Heart Failure After Cancer Treatment
- Saint Christopher's Hospital for Children, Philadelphia
U tijeku regrutacijaOpažajna studija
Sve dobne skupine · Oba spola · Ažurirano 18. svi 2026. · NCT01790152CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
- UPMC Hilman Cancer Center, Pittsburgh
U tijeku regrutacijaFaza 1/2
Od 18 godina i više · Oba spola · Ažurirano 16. tra 2026. · NCT03328078Geriatric Evaluation and Management With Survivorship Health Education for Older Survivors of Cancer, GEM-S Trial
- Geisinger Medical Center, Danville
- Geisinger Cancer Center Dickson City, Dickson City
- Community Medical Center, Scranton
- i još 1
U tijeku regrutacijaFaza 3Zdravi dobrovoljci dobrodošli
Od 18 godina i više · Oba spola · Ažurirano 13. sij 2026. · NCT05006482CD5-deleted Chimeric Antigen Receptor Cells (Senza5 CART5) for T Cell Non-Hodgkin Lymphoma (NHL)
- University of Pennsylvania - Abramson Caner Center, Philadelphia
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 10. stu 2025. · NCT06420089Phase 1 Trial of ST-001 nanoFenretinide in Relapsed/Refractory T-cell Non-Hodgkin Lymphoma
- University of Pittsburgh Medical Center (UPMC), Pittsburgh
U tijeku regrutacijaFaza 1
Od 18 godina i više · Oba spola · Ažurirano 22. ruj 2025. · NCT04234048Iz ClinicalTrials.gov, podaci preuzeti 5. lis 2026.. Svaka studija ima svoje uvjete prihoda; tim studije odlučuje tko se može priključiti.